Treatment of Congenital TTP: Recombinant ADAMTS-13 is Now First-Line
For patients with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) in remission, recombinant ADAMTS-13 is the treatment of choice over fresh frozen plasma, based on a strong 2025 ISTH recommendation with moderate certainty evidence 1.
Treatment Algorithm for Congenital TTP
First-Line: Recombinant ADAMTS-13
- Dose: 40 IU/kg body weight intravenously
- Advantages over plasma:
- Achieves higher and more sustained ADAMTS-13 levels above the protective threshold of 10 IU/dL
- Significantly fewer adverse events (no allergic reactions, anaphylaxis, volume overload, or transfusion-transmitted infections)
- Can be administered in any clinic without specialized equipment or expertise
- Eliminates the logistical burden of plasma infusion 1
The pivotal phase 3 randomized crossover trial demonstrated that while both recombinant ADAMTS-13 and plasma prevented acute TTP events, recombinant therapy showed a trend toward lower incidence of TTP-related manifestations (thrombocytopenia, elevated LDH, neurological symptoms, abdominal pain) and maintained therapeutic ADAMTS-13 levels for longer durations 1.
Second-Line: Fresh Frozen Plasma (When Recombinant ADAMTS-13 Unavailable)
- Current recommendation: FFP is suggested over watch-and-wait approach (very low certainty evidence) 1
- Critical caveat: Regular, scheduled infusions at predefined dosages and intervals are essential—irregular or sporadic plasma infusions do not provide sufficient ADAMTS-13 replacement and fail to prevent long-term complications 1
- Pharmacokinetics: Median half-life of 130 hours (range 82.6-189.5 hours), with patients returning to baseline ADAMTS-13 within 7-10 days post-infusion 2
- Limitations:
- Median peak ADAMTS-13 activity only reaches ~24 IU/dL
- Achieving target trough levels of 50 IU/dL is not feasible due to volume constraints
- Frequent adverse events including allergic reactions, volume overload, and infection risk 1
Important Clinical Considerations
Why Treatment is Essential
The absence of circulating ADAMTS-13 leads to long-term organ damage including cardiovascular disease, end-stage renal disease, and silent ischemic stroke—risks that outweigh the side effects of prophylactic treatment 1, 3. The age of onset and severity of long-term complications correlate directly with residual plasma ADAMTS-13 activity levels.
Geographic Availability
Recombinant ADAMTS-13 is currently approved only in the USA, Europe, and Japan. In regions where it remains unavailable, FFP remains an effective alternative when administered regularly 1.
Pregnancy Considerations
Pregnant patients with cTTP face 10% maternal mortality and >50% fetal loss without prophylaxis, with increased risk of early-onset preeclampsia. Prophylactic ADAMTS-13 replacement during pregnancy is essential to reduce acute events and perinatal mortality 1, 4.
Common Pitfall to Avoid
Do not use irregular, sporadic plasma infusions—this approach does not provide sufficient ADAMTS-13 replacement and was shown in the International Hereditary TTP registry to fail in preventing acute events or reducing long-term complications 1. The 2020 ISTH guidelines' neutral stance on plasma versus watch-and-wait was based on this inadequate dosing strategy.
Shared Decision-Making
The 2025 ISTH guidelines emphasize discussing benefits, potential harms, and treatment burden with patients. Where accessible, recombinant ADAMTS-13 provides the most favorable balance of benefits and risks 1.